These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

403 related items for PubMed ID: 26495976

  • 1. Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® Vaccine.
    Godi A, Bissett SL, Miller E, Beddows S.
    PLoS One; 2015; 10(10):e0140926. PubMed ID: 26495976
    [Abstract] [Full Text] [Related]

  • 2. Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes.
    Barzon L, Squarzon L, Masiero S, Pacenti M, Marcati G, Mantelli B, Gabrielli L, Pascucci MG, Lazzarotto T, Caputo A, Palù G.
    Vaccine; 2014 Sep 15; 32(41):5357-62. PubMed ID: 25045814
    [Abstract] [Full Text] [Related]

  • 3. Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either Cervarix® or Gardasil® vaccine.
    Godi A, Panwar K, Haque M, Cocuzza CE, Andrews N, Southern J, Turner P, Miller E, Beddows S.
    Vaccine; 2019 Apr 24; 37(18):2455-2462. PubMed ID: 30926298
    [Abstract] [Full Text] [Related]

  • 4. A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls.
    Draper E, Bissett SL, Howell-Jones R, Waight P, Soldan K, Jit M, Andrews N, Miller E, Beddows S.
    PLoS One; 2013 Apr 24; 8(5):e61825. PubMed ID: 23650505
    [Abstract] [Full Text] [Related]

  • 5. Cross-neutralizing antibodies elicited by the Cervarix® human papillomavirus vaccine display a range of Alpha-9 inter-type specificities.
    Bissett SL, Draper E, Myers RE, Godi A, Beddows S.
    Vaccine; 2014 Feb 26; 32(10):1139-46. PubMed ID: 24440205
    [Abstract] [Full Text] [Related]

  • 6. Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial.
    Safaeian M, Kemp TJ, Pan DY, Porras C, Rodriguez AC, Schiffman M, Cortes B, Katki H, Wacholder S, Schiller JT, Gonzalez P, Penrose K, Lowy DR, Quint W, van Doorn LJ, Herrero R, Hildesheim A, Pinto LA.
    Hum Vaccin Immunother; 2013 Jul 26; 9(7):1399-406. PubMed ID: 23571174
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparison of the immunogenicity of Cervarix® and Gardasil® human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults.
    Toft L, Tolstrup M, Müller M, Sehr P, Bonde J, Storgaard M, Østergaard L, Søgaard OS.
    Hum Vaccin Immunother; 2014 Jul 26; 10(5):1147-54. PubMed ID: 24553190
    [Abstract] [Full Text] [Related]

  • 9. Sustained Antibody Responses 6 Years Following 1, 2, or 3 Doses of Quadrivalent Human Papillomavirus (HPV) Vaccine in Adolescent Fijian Girls, and Subsequent Responses to a Single Dose of Bivalent HPV Vaccine: A Prospective Cohort Study.
    Toh ZQ, Russell FM, Reyburn R, Fong J, Tuivaga E, Ratu T, Nguyen CD, Devi R, Kama M, Matanitobua S, Tabrizi SN, Garland SM, Sinha R, Frazer I, Tikoduadua L, Kado J, Rafai E, Mulholland EK, Licciardi PV.
    Clin Infect Dis; 2017 Apr 01; 64(7):852-859. PubMed ID: 28034886
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice.
    Chen X, Zhang T, Liu H, Hao Y, Liao G, Xu X.
    Hum Vaccin Immunother; 2018 Apr 01; 14(8):2025-2033. PubMed ID: 29683766
    [Abstract] [Full Text] [Related]

  • 12. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years.
    Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B, Scholar S, Rosen J, Chakhtoura N, Meric D, Dessy FJ, Datta SK, Descamps D, Dubin G, HPV-010 Study Group.
    Hum Vaccin; 2011 Dec 01; 7(12):1343-58. PubMed ID: 22048173
    [Abstract] [Full Text] [Related]

  • 13. Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes.
    Godi A, Boampong D, Elegunde B, Panwar K, Fleury M, Li S, Zhao Q, Xia N, Christensen ND, Beddows S.
    J Virol; 2020 Nov 23; 94(24):. PubMed ID: 32967963
    [Abstract] [Full Text] [Related]

  • 14. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.
    Jagu S, Karanam B, Gambhira R, Chivukula SV, Chaganti RJ, Lowy DR, Schiller JT, Roden RB.
    J Natl Cancer Inst; 2009 Jun 03; 101(11):782-92. PubMed ID: 19470949
    [Abstract] [Full Text] [Related]

  • 15. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years.
    Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, Carletti I, Dessy FJ, Trofa AF, Schuind A, Dubin G, HPV-010 Study Group.
    Hum Vaccin; 2009 Oct 03; 5(10):705-19. PubMed ID: 19684472
    [Abstract] [Full Text] [Related]

  • 16. Sensitivity of Human Papillomavirus (HPV) Lineage and Sublineage Variant Pseudoviruses to Neutralization by Nonavalent Vaccine Antibodies.
    Godi A, Kemp TJ, Pinto LA, Beddows S.
    J Infect Dis; 2019 Nov 06; 220(12):1940-1945. PubMed ID: 31412122
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial.
    Toft L, Storgaard M, Müller M, Sehr P, Bonde J, Tolstrup M, Østergaard L, Søgaard OS.
    J Infect Dis; 2014 Apr 15; 209(8):1165-73. PubMed ID: 24273179
    [Abstract] [Full Text] [Related]

  • 18. Developments in L2-based human papillomavirus (HPV) vaccines.
    Schellenbacher C, Roden RBS, Kirnbauer R.
    Virus Res; 2017 Mar 02; 231():166-175. PubMed ID: 27889616
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.